Nichi-Iko has disclosed that it is currently engaged in consultations with the FDA concerning the demonstration of interchangeability of its proposed biosimilar with the reference Remicade.
Last month, Tokyo-based biosimilar developer Nichi-Iko announced that its biosimilar infliximab, NI-071 had been approved by Japan’s Ministry of Labor, Health, and Welfare. The biosimilar infliximab will be jointly marketed in Japan by ZERIA Pharmaceutical Co.
The biosimilar developer has also begun a phase 3 clinical program in the United States with an eye toward eventual FDA approval for its biosimilar; the RADIANCE trial—conducted by Nichi-Iko’s US subsidiary, Sagent Pharmaceuticals—will evaluate the similarity of NI-071 and the US-approved originator infliximab (Remicade) in terms of safety and efficacy in patients with rheumatoid arthritis who have not responded adequately to methotrexate.
Nichi-Iko also disclosed that it is currently engaged in consultations with the FDA concerning the demonstration of interchangeability of the proposed biosimilar with the reference Remicade. The United States is alone among regulatory bodies in requiring an FDA designation of interchangeability for a biosimilar before it can be substituted for its reference at the pharmacy level. The fact that the FDA has not yet published its final interchangeability guidance poses a distinct challenge to biosimilar developers seeking the additional level of regulatory clearance. However, in July, FDA officials signaled that the interchangeable biosimilars could begin to gain approval within the next 2 years.
If Nichi-Iko is successful in bringing an infliximab biosimilar to the US marketplace, NI-071 would join biosimilars made by Pfizer (Inflectra) and Merck (Renflexis) in competing with Remicade for a place on insurers’ formularies. Analysts predict that competition among biosimilar infliximab therapies will serve as a bellwether for how successful the US biosimilars market could be in the coming years.
So far, Johnson and Johnson has largely maintained its market share for infliximab, though biosimilar challengers question its methods; in September, Pfizer filed a district court lawsuit against Johnson and Johnson for allegedly engaging in exclusionary formulary contracting and anti-competitive practices that have effectively denied patients access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.